Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Opdivo plus Yervoy as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced HCC.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, an
Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%.
The latest trading day saw Bristol Myers Squibb (BMY) settling at $60.62, representing a +1.59% change from its previous close.
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Presents Results from CheckMate -8HW.
Bloomsbury Publishing PLC (LSE:BMY),  the home of authors such as Sarah J. Maas and J.K.

Final Trade: ET, DELL, KRE, BMY

06:31pm, Thursday, 23'rd Jan 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to
The latest trading day saw Bristol Myers Squibb (BMY) settling at $56.29, representing a -0.16% change from its previous close.
Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in s
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE